Overseas equities are outperforming domestic shares for the first time in about 15 years, and some financial pros say it’s ...

By integrating foundation models into its R&D pipeline, AstraZeneca seeks to enable data-driven discovery methods.

The approval comes amid speculation that the big pharma company may switch its UK stock market listing to the US.

Summit Therapeutics nears a $15B AstraZeneca deal for ivonescimab, targeting a $90B market. See more on the potential and ...

It might be gearing up to pay billions of dollars to participate in a drug program currently in development. AstraZeneca ...

UK pharma major AstraZeneca is in talks with Summit Therapeutics to license an experimental lung-cancer drug under a deal ...

British drugmaker AstraZeneca (LSE: AZN) has gained European approval for Imfinzi (durvalumab) in combination with ...

The FTSE 100 and European stocks were jittery on Friday, moving lower while US markets were closed for 4 July, as investors ...

Drugmaker AstraZeneca said on Friday that its Imfinzi asset has been approved in the EU as the first and only perioperative ...

The European Commission has cleared OD-L1 inhibitor Imfinzi (durvalumab) to treat adults with resectable muscle-invasive ...